Pat Gleason, PharmD, FCCP, BCPS, director of health outcomes, Prime Therapeutics, and Shelley Sanchez, senior director of specialty product development, Prime Therapeutics, presented on 1 approach to managing the specialty drug benefit, which includes optimizing the use of PhARMA manufacturer coupons and patient assistance programs (PAPs).
Pat Gleason, PharmD, FCCP, BCPS, director of health outcomes, Prime Therapeutics, and Shelley Sanchez, senior director of specialty product development, Prime Therapeutics, presented on 1 approach to managing the specialty drug benefit, which includes optimizing the use of PhARMA manufacturer coupons and patient assistance programs (PAPs). Prime Therapeutics research is particularly focused on trends and findings that coupons and PAPs have on patients’ out-of-pocket (OOP) costs. Prime has always had a unique focus on specialty drug management. Its unique connections, medical data, and pharmacy data all result in “superior member experiences” and more affordable medications.
“Let me tell you a little about me, I love couponing,” said Ms Sanchez. “My husband, however, is from Spain and cannot understanding couponing. “ Ms Sanchez explains that her story is not unlike others in the patient community as the “coupon craze” has expanded into the pharmaceutical industry.
Ms Sanchez went on to suggest that double-digit specialty trend is a result of utilization, drug mix, and price inflation. By 2018, Prime projects that specialty drug spending will account for more than half of overall spending. This means that payers’ total drug bills could double within the next 10 years.
The presenters offer 7 steps to managing the specialty trend:
1. Bridge the benefit divide
2. Focus on the biggest issues
3. Narrow the specialty network
4. Embrace the management mind-set
5. Promote preferred drug use
6. Protect members from high specialty costs
7. Pick the right partner
Prime Therapeutics specialty pharmacy management program saved patients over $21.2 million in 2013. They also reported that 19,862 patients (a little more than half) received a co-pay offset, and there was a $1069 average savings per patient who received any co-pay offset. Dr Gleason stressed that while there is a limited amount of evidence to the value coupons/PAPs have on patient cost share, coupons are just 1 way to help members save. They should be used to complement other care features such as care management, benefit design, formulary rebates, utilization management, and a patient’s/provider’s network.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More